Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 16/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30684862 | 0.80 | PIM1 (0.40) | GRM5 | |
| SCHEMBL3371217 | 0.76 | GRM5 (0.59) | GRM5 | |
| SCHEMBL3371568 | 0.73 | GRM5 (0.41) | GRM5 | |
| SCHEMBL3372611 | 0.72 | GRM5 (0.38) | GRM5 | |
| SCHEMBL3406745 | 0.72 | GRM5 (0.50) | GRM5 | |
| SCHEMBL19664854 | 0.72 | KMO (0.42) | — | |
| SCHEMBL3404720 | 0.72 | DPP4 (0.40) | GRM5 | |
| SCHEMBL16799586 | 0.70 | GRM5 (0.44) | GRM5 | |
| SCHEMBL3370931 | 0.70 | GRM5 (0.54) | GRM5 | |
| SCHEMBL28948723 | 0.69 | CCNA2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117088885-A | Triazolopyridazine compound and application thereof | 上海赛默罗生物科技有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-10227362-B2 | Anti-pulmonary tuberculosis nitroimidazole derivative | MEDSHINE DISCOVERY INC. (CN) | 2019-03-12 | — | — | US | disclosed |
| US-20180162878-A1 | ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE | MEDSHINE DISCOVERY INC. (CN) | 2018-06-14 | — | — | US | disclosed |
| EP-3252059-A1 | ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE | Medshine Discovery Inc. (CN) | 2017-12-06 | — | — | EP | disclosed |
| CN-107207532-A | Nitroimidazole derivatives against tuberculosis | 南京明德新药研发股份有限公司 | 2017-09-26 | — | — | CN | disclosed |
| WO-2010052222-A1 | (DIHYDRO)NAPHTHYRIDINONE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162878-A1 | ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE | NDUFV1, NDUFV2, MT-ND4 | GRM5 3594/4885 |
| US-10227362-B2 | Anti-pulmonary tuberculosis nitroimidazole derivative | NDUFV1, NDUFV2, MT-ND4 | GRM5 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.